Founding Organizations:

In this dynamic and engaging presentation, Dr. Sujit Janardhan brings energy, insight, and humor to a deep dive on the evolving landscape of fatty liver disease—now known as metabolic dysfunction-associated steatohepatitis (MASH). Developed in collaboration with the Chronic Liver Disease Foundation and the Global NASH Council, this session is designed for any provider managing patients with MASH. Learn about the recommended non-invasive testing (NIT) algorithm to identify advanced fibrosis, including how to use FIB-4, ELF score, and transient elastography to risk-stratify patients and guide care. Dr. Loomba discusses the epidemiologic rise of MASH and its strong association with metabolic syndrome, diabetes, and cardiovascular mortality. The session covers the three pillars of management—lifestyle intervention, pharmacologic therapy (including the newly FDA-approved resmetirom), and referral for clinical trials in advanced cases. Gain practical, evidence-based strategies to recognize high-risk patients, interpret NIT results, and integrate therapies that target both hepatic and metabolic outcomes. If you're managing patients with obesity, type 2 diabetes, or unexplained liver test abnormalities, this presentation will equip you with actionable tools to improve outcomes and reduce progression to cirrhosis and liver-related complications.